Mirtazapine: A Review of its Use in Major Depression and Other Psychiatric Disorders
The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
Abstract
Mirtazapine (Remeron, Zispin) is a noradrenergic and specific serotonergic antidepressant (NaSSA) that is approved in many counties for use in the treatment of major depression. Monotherapy with mirtazapine 15-45 mg/day leads to rapid and sustained improvements in depressive symptoms in patients with major depression, including the elderly. It is as effective as other antidepressants and may have a more rapid onset of action than selective serotonin reuptake inhibitors (SSRIs). Furthermore, it may also have a higher sustained remission rate than amitriptyline. Preliminary data suggest that mirtazapine may also be effective in the treatment of anxiety disorders (including post-traumatic stress disorder, panic disorder and social anxiety disorder), obsessive-compulsive disorder, undifferentiated somatoform disorder and, as add-on therapy, in schizophrenia, although large, well designed trials are needed to confirm these findings. Mirtazapine is generally well tolerated in patients with depression. In conclusion, mirtazapine is an effective antidepressant for the treatment of major depression and also has the potential to be of use in other psychiatric indications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, TCAs can antagonize 5-HT 2A and 5-HT 2C , thereby increasing the release of NE and DA in cortical areas. 348 – 350”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [348]
Citations
Cites
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Prevalence and Incidence Studies of Mood Disorders: A Systematic Review of the Literature
Waraich, P., Goldner, E. M., Somers, J. M., & Hsu, L. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404900208 · Cited by 522
Fava, M., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Alpert, J. E., McGrath, P. J., Thase, M. E., Warden, D., Biggs, M., Luther, J. F., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.7.1161 · Cited by 362
McGrath, P. J., Stewart, J. W., Fava, M., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Thase, M. E., Davis, L., Biggs, M. M., Shores-Wilson, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1531 · Cited by 350
The underrecognition and undertreatment of depression: what is the breadth and depth of the problem?
Davidson, J. R. T., & Meltzer-Brody, S. E. (1999) · PubMed · Cited by 320
Clinical Pharmacokinetics of Mirtazapine
Timmer, C. J., Ad Sitsen, J. M., & Delbressine, L. P. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038060-00001 · Cited by 319
Davidson, J. R. T., DuPont, R. L., Hedges, D., & Haskins, J. T. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0805 · Cited by 303
Fawcett, J., & Barkin, R. L. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0306 · Cited by 266
Restless legs syndrome as side effect of second generation antidepressants
Rottach, K. G., Schaner, B. M., Kirch, M. H., Zivotofsky, A. Z., Teufel, L. M., Gallwitz, T., & Messer, T. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.02.006 · Cited by 249
Double-Blind, Randomized Comparison of Mirtazapine and Paroxetine in Elderly Depressed Patients
Schatzberg, A. F., Kremer, C., Rodrigues, H. E., & Murphy, G. M. (2002) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200209000-00007 · Cited by 215
Research works printed but not linked: 13
- Bruijn, 1996, Psychopharmacol, 127, 231, 10.1007/BF02246131 · doi:10.1007/bf02246131
- Kinoshita, 2009, Jpn J Clin Psychopharmacol, 12, 289
- Kinoshita, 2009, Jpn J Clin Psychopharmacol, 12, 503
- Bremner, 1995, J Clin Psychiatry, 56, 519
- Smith, 1990, Psychopharmacol Bull, 26, 191
- Wade, 2003 May, Int Clin Psychopharmacol, 18, 133
- van Willigenburg, 2004, World J Biol Psych, 5, 93
- Barilla, 2004, World J Biol Psych, 5, 93
- Weiser, 2004 Jun 14, Mov Disord, 19, 205
- Brown, 1999, Eur J Psychiatry, 13, 197
- Brown, 2000, Eur J Psychiatry, 14, 15
- Norinder, 2000 Apr 5, Lakartidningen, 97, 1693
- Ravindran, 2005, Geriatrics Aging, 8, 20
Cited by
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Review of Safety and Efficacy of Sleep Medicines in Older Adults
Schroeck, J. L., Ford, J., Conway, E. L., Kurtzhalts, K. E., Gee, M. E., Vollmer, K. A., & Mergenhagen, K. A. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.09.010 · Cited by 373
Narouze, S., Benzon, H. T., Provenzano, D. A., Buvanendran, A., De Andres, J., Deer, T. R., Rauck, R., & Huntoon, M. A. (2015) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000223 · Cited by 362
Yuan, M., Yang, B., Rothschild, G., Mann, J. J., Sanford, L. D., Tang, X., Huang, C., Wang, C., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01519-z · Cited by 246
Metadata
- Authors
- Croom, K. F., Perry, C. M., & Plosker, G. L.
- Affiliations
- Wolters Kluwer Health (NZ)
- Corresponding author
- Plosker, Greg L.
- Venue
- CNS Drugs
- Published
- 2009-05
- Volume
- 23
- Issue
- 5
- Pages
- 427-452
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W2000591684
- Cited by
- 158
- References
- 129
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 9 · 2023: 8 · 2022: 10 · 2021: 10 · 2020: 9 · 2019: 7 · 2018: 8 · 2017: 13 · 2016: 5 · 2015: 8 · 2014: 6 · 2013: 10 · 2012: 17
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- mirtazapine, noradrenergic and specific serotonergic antidepressants, major depressive disorder, antidepressant efficacy, pharmacokinetics, pharmacodynamics, drug interactions, adverse effects, sleep improvement, anxiety disorders, post-traumatic stress disorder, obsessive-compulsive disorder, schizophrenia, elderly patients, REM sleep, enantiomers, CYP3A4, CYP2D6
- MeSH terms
- Mirtazapine, Antidepressive Agents, Tricyclic, Anxiety Disorders, Major Depressive Disorder, Humans, Mianserin, Psychiatric Status Rating Scales, Databases, Bibliographic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mirtazapine: A Review of its Use in Major Depression and Other Psychiatric Disorders. https://app.cochat.ai/papers/10.2165/00023210-200923050-00006
- The paper
- Croom, K. F., Perry, C. M., & Plosker, G. L. (2009). Mirtazapine: A Review of its Use in Major Depression and Other Psychiatric Disorders. CNS Drugs. https://doi.org/10.2165/00023210-200923050-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.